Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 13/20 | 0.44 |
| ▸ | CA2 | P00918 | 13/20 | 0.44 |
| ▸ | CA12 | O43570 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 9/20 | 0.44 |
| ▸ | CA6 | P23280 | 5/20 | 0.44 |
| ▸ | CA7 | P43166 | 5/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.44 |
| ▸ | CA5A | P35218 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13947629 | 0.85 | CA1 (0.49) | CA1CA2CA12CA9CA6 | |
| SCHEMBL15114555 | 0.83 | TRPV4 (0.53) | TRPV4ALDH1A1GAALMNAL3MBTL1 | |
| SCHEMBL2926545 | 0.83 | TRPV4 (0.73) | TRPV4ALDH1A1GAALMNAKDM4E | |
| SCHEMBL4629169 | 0.79 | PDIA6 (0.49) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL7952694 | 0.79 | ALDH1A1 (0.55) | CA1CA2CA12CA9CA6 | |
| SCHEMBL23598880 | 0.78 | PTGS1 (0.41) | TRPV4CA1CA2CA12CA9 | |
| SCHEMBL16259892 | 0.77 | TRPV4 (0.47) | TRPV4ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL2393783 | 0.77 | CA1 (0.42) | TRPV4CA1CA2CA12CA9 | |
| SCHEMBL23901714 | 0.76 | ALDH1A1 (0.39) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL16259574 | 0.76 | TRPV4 (0.46) | TRPV4ALDH1A1LMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021133915-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | TRPV4 3516/4885CA1 4719/4885CA2 4693/4885 |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | TRPV4 611/4885CA1 4506/4885CA2 3289/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | TRPV4 1084/4885CA1 4518/4885CA2 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.